Autosomal Dominant Hypercholesterolemia 3: Disease-Characteristics Report

Executive summary and evidence scope

Autosomal dominant hypercholesterolemia 3 (ADH3; FH3/HCHOLA3) is the rare familial-hypercholesterolemia subtype caused by heterozygous germline gain-of-function (GOF) variants in PCSK9. Excess PCSK9 activity decreases hepatocyte-surface LDL receptor (LDLR), causing lifelong elevation of LDL cholesterol (LDL-C), cumulative arterial cholesterol exposure, and premature atherosclerotic cardiovascular disease (ASCVD). The phenotype overlaps LDLR- and APOB-associated familial hypercholesterolemia (FH), so ADH3 is defined molecularly rather than by unique clinical findings. Direct ADH3 evidence is dominated by pedigrees and functional studies; most management and outcome estimates necessarily come from broader heterozygous FH cohorts.

Table: This table separates evidence specific to PCSK9 gain-of-function ADH3 from findings extrapolated from familial hypercholesterolemia generally. It summarizes defining genetics, phenotype, diagnosis, management, screening, quantitative findings, and major evidence gaps.

1. Disease information

Definition, names, and identifiers

Preferred name: autosomal dominant hypercholesterolemia 3. Common alternatives are ADH3, familial hypercholesterolemia 3, FH3, HCHOLA3, PCSK9-related familial hypercholesterolemia, and PCSK9 gain-of-function hypercholesterolemia. The original locus was mapped to chromosome 1p32, and the 2003 landmark study identified PCSK9 variants in two linked French families. Its abstract states that the investigators “mapped a third locus associated with ADH, HCHOLA3 at 1p32” and found two causal PCSK9 mutations. DOI: https://doi.org/10.1038/ng1161; publication: June 2003. (seidah2017thepcsk9revolution pages 3-6, abifadel2003mutationsinpcsk9 pages 2-2)

Identifier caution: the retrieved primary literature uses MIM 607786 for the PCSK9-associated hypercholesterolemia phenotype and MIM 607786/603776-related notation in older records; an older article also cites MIM 143890 for the broader ADH phenotype. These historical numbers should be reconciled directly against the current OMIM record before database ingestion. A definitive subtype-specific MONDO identifier was not recovered by the available tools; use the current MONDO familial-hypercholesterolemia parent mapping only after curator verification. Broader coding generally uses familial/pure hypercholesterolemia categories (for example ICD-10-CM E78.01), because ICD and MeSH do not ordinarily distinguish ADH3 by gene. (allard2005novelmutationsof pages 1-3)

Data provenance: the disease definition and variant–phenotype relationships derive from aggregated disease resources, pedigrees, lipid-clinic cohorts, and experimental studies—not individual-level EHR data in this report. Recent implementation studies use aggregated clinical records, but their findings concern FH generally rather than PCSK9-genotyped ADH3.

2. Etiology, risk, protection, and gene–environment interaction

Primary cause

ADH3 is caused by a germline PCSK9 GOF allele. Pathogenicity is mechanism-specific: rare PCSK9 variants can be GOF, loss-of-function (LOF), neutral, or uncertain, so merely finding a rare PCSK9 allele is insufficient. GOF mechanisms include enhanced LDLR binding, altered intracellular trafficking or secretion, resistance to inactivation, increased stability, and reduced inhibitory binding of PCSK9 to LDL particles. A 2024 review estimated that PCSK9 GOF variants cause approximately 1% of FH and listed about 36 pathogenic/probably pathogenic variants, although database totals evolve. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5)

Risk factors and modifiers

• Genetic: one pathogenic PCSK9 GOF allele, a second pathogenic FH allele, high polygenic LDL-C burden, and other ASCVD-risk alleles can increase severity. A PCSK9 p.Arg469Trp carrier with a coexisting LDLR frameshift had especially severe disease, illustrating additive monogenic effects. Expressivity also varied among p.Arg218Ser relatives. (allard2005novelmutationsof pages 3-6, allard2005novelmutationsof pages 1-3)
• Clinical/environmental: smoking, hypertension, diabetes, obesity, inactivity, an atherogenic diet, elevated lipoprotein(a), and delayed or inadequate LDL-lowering do not cause ADH3 but increase downstream ASCVD risk. Lifelong LDL exposure begins at birth; broader FH guidance therefore treats cumulative LDL-C as the dominant causal exposure. (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9, watts2023internationalatherosclerosissociety pages 1-2, watts2023internationalatherosclerosissociety pages 7-8)
• Pregnancy: physiological lipid increases can magnify hypercholesterolemia; markedly high cholesterol during pregnancy was reported in a p.Arg357His carrier. (allard2005novelmutationsof pages 1-3)

Protective factors

PCSK9 LOF alleles lower LDL-C and coronary risk but are not a practical within-patient “protective modifier” once a causal GOF allele is present. Environmental protection consists chiefly of early sustained LDL-C lowering, smoking avoidance, exercise, heart-healthy dietary patterns, normal weight, and control of blood pressure and diabetes. These interventions reduce cardiovascular consequences, not inheritance of ADH3. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, mcnutt2010characterizationofthea pages 115-119)

A gene–treatment interaction is important: statins activate SREBP2 and increase both LDLR and PCSK9 expression. PCSK9 blockade preserves more of the statin-induced LDLR, explaining their mechanistic synergy. (mcnutt2010characterizationofthe pages 115-119, mcnutt2010characterizationofthea pages 115-119)

3. Phenotypes

ADH3-specific phenotype frequencies cannot be estimated reliably from the small published pedigrees. Suggested ontology annotations are therefore qualitative.

• Elevated LDL-C / type IIa hyperlipoproteinemia—laboratory abnormality, present from birth, chronic and usually progressive in cumulative impact; severity ranges from mild to very severe. Suggested HPO: Hypercholesterolemia (HP:0003124) and Elevated circulating LDL cholesterol concentration. A p.Arg218Ser proband had untreated total cholesterol 402 mg/dL and LDL-C 293 mg/dL at age 45. (allard2005novelmutationsof pages 3-6)
• Tendon xanthoma—physical sign caused by cholesterol deposition, usually appearing after prolonged severe exposure but potentially in childhood in severe FH. Suggested HPO: Tendon xanthomatosis (HP:0000991). The p.Arg218Ser proband had tendinous xanthoma. (allard2005novelmutationsof pages 3-6)
• Corneal arcus—bilateral peripheral corneal lipid deposition, particularly informative when premature. Suggested HPO: Corneal arcus (HP:0001084). It was present in the same p.Arg218Ser proband. (allard2005novelmutationsof pages 3-6)
• Premature coronary atherosclerosis, angina, myocardial infarction, and cardiovascular death—downstream complications, age-dependent and progressive. Suggested HPO: Premature atherosclerosis (HP:0002621), Coronary artery disease (HP:0001677), and Myocardial infarction (HP:0001658). An original p.Phe216Leu carrier died from myocardial infarction at 49 years; p.Asp374Tyr is associated with particularly severe disease and premature cardiovascular death. (weider2017inhibitionofthe pages 152-156, abifadel2003mutationsinpcsk9 pages 2-2)
• Aortic/other arterial atherosclerosis—expected from the FH disease process, but no reliable ADH3-specific frequency was recovered.

Quality of life is usually unaffected by the biochemical phenotype itself until treatment burden, anxiety, xanthomas, angina, or vascular events intervene. No ADH3-specific EQ-5D, SF-36, or PROMIS study was identified. In general FH, childhood treatment is expected to improve quality of life and reduce later mortality. (watts2023internationalatherosclerosissociety pages 1-2)

4. Genetic and molecular information

Causal gene: PCSK9, chromosome 1p32.3; HGNC:20001 (curator should verify current HGNC/Ensembl cross-references). It encodes proprotein convertase subtilisin/kexin type 9, formerly NARC-1. PCSK9 is synthesized as a zymogen and autocatalytically cleaved in the endoplasmic reticulum; cleavage enables ER exit. (seidah2017thepcsk9revolution pages 3-6, abifadel2003mutationsinpcsk9 pages 2-2)

Representative variants

• p.Ser127Arg (S127R) and p.Phe216Leu (F216L): original heterozygous variants establishing causality. S127R affects the prodomain/processing region and can inhibit normal LDL binding; F216L lies near catalytic His226. (seidah2017thepcsk9revolution pages 3-6, abifadel2003mutationsinpcsk9 pages 2-2)
• p.Asp374Tyr (D374Y): strong GOF missense variant with approximately tenfold greater LDLR affinity, severe hypercholesterolemia, and premature cardiovascular disease. (weider2017inhibitionofthe pages 152-156, rochemolina2015inductionofsustained pages 1-2)
• p.Arg218Ser (R218S): heterozygous catalytic-domain variant that cosegregated in four relatives and was absent from 415 diverse controls; functional effect was not demonstrated in the original report, so modern classification should incorporate current ClinVar/ClinGen evidence. (allard2005novelmutationsof pages 3-6)
• p.Arg357His, p.Ala443Thr, and p.Arg469Trp: reported in LDLR/APOB-negative ADH screening; original evidence and segregation strength varied. (allard2005novelmutationsof pages 1-3)
• Regulatory variation: a 2024 study of 409 suspected-FH patients found rare LDLR/PCSK9 3′UTR variants; PCSK9 c.*950C>T increased reporter expression by 41%. This is emerging FH evidence and should not automatically be labeled definitive ADH3 without segregation and clinical functional validation. DOI: https://doi.org/10.1155/2024/9964734; February 2024. (otero2024functionalanalysisof pages 4-5)

All established disease alleles are germline. Somatic origin is not characteristic. Most reported alleles are missense; the functional endpoint is GOF rather than simple haploinsufficiency. Population frequency should be extremely low for highly penetrant pathogenic alleles, but exact gnomAD frequencies must be entered variant by variant. No recurrent chromosomal abnormality, repeat expansion, mitochondrial defect, or disease-defining structural variant is established.

Modifiers and epigenetics

No validated ADH3-specific modifier gene or epigenetic lesion is established. A 2024 FH study found differential LDLR, PCSK9, and LDLRAP1 methylation associated with clinical manifestations and cardiovascular events in 131 patients, but this remains a potential biomarker in mixed-genotype FH, not a proven cause or modifier of ADH3.

5. Environmental information

No toxin, radiation exposure, occupational agent, or infectious pathogen causes ADH3. Diet, adiposity, inactivity, smoking, diabetes, and hypertension modify LDL-C or vascular consequences. Infectious-agent and zoonotic fields are not applicable. Lifestyle intervention is necessary but is rarely sufficient to normalize genetically elevated LDL-C. General FH evidence shows that cumulative pathogenic LDL exposure can be reached by approximately age 12.5 years versus around 55 years without FH, emphasizing that lifestyle advice must not delay pharmacotherapy. (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)

6. Mechanism and pathophysiology

Ordered causal chain

1. A germline PCSK9 GOF variant leads to increased effective PCSK9 activity through enhanced LDLR affinity, altered trafficking/secretion, increased stability, impaired inactivation, or loss of normal LDL-mediated inhibition.
2. Increased active PCSK9 leads to greater binding of LDLR’s EGF-A domain at the hepatocyte surface and/or within the secretory pathway.
3. The PCSK9–LDLR complex results in sorting to late endosomes and lysosomes rather than recycling of LDLR to the plasma membrane.
4. Accelerated LDLR degradation leads to reduced cell-surface LDLR on hepatocytes.
5. Reduced receptor abundance results in impaired hepatic uptake of apoB-containing LDL particles and lifelong elevation of plasma LDL-C.
6. Chronic LDL-C exposure leads to arterial-wall LDL retention and modification.
7. Retained lipoprotein results in endothelial dysfunction and macrophage uptake/foam-cell formation; direct LDLR-independent PCSK9 inflammatory effects are plausible but remain less firmly demonstrated in human ADH3.
8. Lipid accumulation, inflammation, smooth-muscle responses, oxidative stress, calcification, and fibrous-cap remodeling lead to progressive atherosclerotic plaque.
9. Plaque growth or rupture results in coronary disease, myocardial infarction, stroke, and premature death; extravascular cholesterol deposition branches to tendon xanthomas and corneal arcus. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, mcnutt2010characterizationofthe pages 115-119, rochemolina2015inductionofsustained pages 1-2, weider2017inhibitionofthea pages 152-156)

The upstream lesion is variant-specific PCSK9 GOF; LDLR depletion and high LDL-C are central demonstrated intermediates. Arterial inflammation and tissue injury are downstream. D374Y increases PCSK9–LDLR affinity by at least tenfold. S127R/D129G can show abnormal secretion or intracellular activity, demonstrating that not all variants act identically. (rochemolina2015inductionofsustained pages 1-2, matiasperez2021pcsk9geneparticipates pages 2-4)

Suggested GO terms: regulation of receptor-mediated endocytosis; low-density lipoprotein particle receptor catabolic process; cholesterol homeostasis; lipoprotein metabolic process; endosomal transport; lysosomal protein catabolic process; receptor recycling; foam-cell differentiation; inflammatory response; response to oxidative stress.

Suggested Cell Ontology terms: hepatocyte (CL:0000182) as the principal causal cell; enterocyte (CL:0000584), macrophage (CL:0000235), endothelial cell (CL:0000115), vascular smooth-muscle cell, pancreatic beta cell, and adipocyte as secondary/contextual populations.

Molecular profiling is limited. No ADH3-specific clinical single-cell, spatial-transcriptomic, proteomic, or multi-omic atlas was identified. A genome-wide expression analysis of D374Y-expressing cells and newer methylation/3′UTR studies are exploratory rather than diagnostic. PCSK9 is regulated with LDLR by SREBP2 and is expressed mainly in hepatocytes, with lower expression reported in intestine, kidney, pancreatic islets, and cerebellum. (mcnutt2010characterizationofthe pages 115-119, weider2017inhibitionofthea pages 152-156, weider2017inhibitionofthe pages 64-68)

7. Anatomical structures affected

• Primary organ/process: liver—hepatocytes regulate circulating LDL clearance. Suggested UBERON: liver (UBERON:0002107).
• Primary injured system: cardiovascular system, especially coronary arteries and aorta. Suggested UBERON: aorta (UBERON:0000947), coronary artery, arterial wall/intima, and heart.
• Secondary deposition sites: tendons and corneal periphery; usually bilateral/systemic rather than lateralized.
• Subcellular compartments: endoplasmic reticulum, Golgi/trans-Golgi network, plasma membrane, endosome, late endosome, and lysosome. Corresponding GO Cellular Component annotations should include ER lumen, Golgi apparatus, cell surface, endosome, and lysosome. PCSK9’s C-terminal domain supports trafficking of the PCSK9–LDLR complex toward late endocytic compartments. (mcnutt2010characterizationofthe pages 115-119, rochemolina2015inductionofsustained pages 1-2, weider2017inhibitionofthea pages 152-156)

8. Temporal development

The biochemical phenotype begins from birth because the causal allele is constitutional. Clinical onset is chronic and insidious. Early-stage disease consists of isolated LDL-C elevation; intermediate disease may include arcus, tendon xanthomas, and subclinical plaque; advanced disease includes symptomatic coronary or other arterial disease. The course is lifelong and cumulative, not episodic or spontaneously remitting. Treatment can normalize or substantially reduce LDL-C and arrest or delay complications but does not eliminate the genotype. Childhood is the critical preventive window. In broader FH cohorts treated from youth, ASCVD occurred in 1% of treated offspring versus 26% of affected parents, and mortality was 0% versus 7%, supporting early intervention even though these figures are not ADH3-specific. (watts2023internationalatherosclerosissociety pages 9-10)

9. Inheritance and population

Inheritance is autosomal dominant; each child of a heterozygous affected individual has a 50% transmission probability. Penetrance for elevated LDL-C is considered high but is age-, variant-, treatment-, and threshold-dependent. Expressivity is variable, as demonstrated within the p.Arg218Ser family. Anticipation is not established. Germline mosaicism is theoretically possible but not a recognized recurrent feature; consanguinity is not required. Biallelic GOF variants or dual molecular diagnoses may cause an HoFH-like extreme phenotype. (allard2005novelmutationsof pages 3-6, watts2023internationalatherosclerosissociety pages 1-2)

Reliable ADH3-specific prevalence, incidence, carrier frequency, sex ratio, and geographic distribution are unavailable. PCSK9 GOF variants account for about 1% of FH in a recent review and 2.3% of LDLR/APOB-negative cases in one selected 130-patient series; these are not population-prevalence estimates. General heterozygous FH prevalence is approximately 1:311, or more than 34 million people worldwide. Males and females inherit ADH3 equally, although sex and conventional risk factors may alter event timing. (allard2005novelmutationsof pages 1-3, fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5, marquina2024costeffectivenessofscreening pages 1-2)

Founder effects may occur for individual alleles, but no single global ADH3 founder variant was established in the retrieved evidence.

10. Diagnostics

Clinical and biochemical assessment

Obtain at least two fasting or nonfasting lipid profiles where feasible, documenting untreated or estimated pretreatment LDL-C. Assess family history of markedly elevated LDL-C and premature ASCVD, tendon xanthomas, corneal arcus, blood pressure, diabetes, smoking, renal/liver/thyroid status, and lipoprotein(a). Use a validated FH framework such as Dutch Lipid Clinic Network, Simon Broome, MEDPED, or a national pediatric criterion. General FH guidelines characterize the triad as hyper-LDL-cholesterolemia, premature coronary disease, and tendon/skin xanthomas. (watts2023internationalatherosclerosissociety pages 7-8, yip2023geneticspectrumand pages 5-6)

Exclude secondary hypercholesterolemia: hypothyroidism, nephrotic syndrome, cholestatic liver disease, chronic kidney disease, uncontrolled diabetes, medications, and severe dietary causes. Molecular differential diagnosis includes LDLR-related FH, APOB-related familial defective apoB, APOE p.Leu167del hypercholesterolemia, LDLRAP1-related recessive hypercholesterolemia, ABCG5/ABCG8 sitosterolemia, polygenic hypercholesterolemia, and elevated lipoprotein(a).

Genetic testing

Use an accredited NGS FH panel including at least LDLR, APOB, PCSK9, and LDLRAP1, with deletion/duplication analysis and additional validated genes where appropriate. A pathogenic/likely pathogenic PCSK9 GOF allele plus a compatible phenotype confirms ADH3. Report VUS separately and do not use one alone for predictive diagnosis. Functional evidence is unusually important because PCSK9 has both GOF and LOF alleles. Family segregation and targeted testing of relatives strengthen interpretation. (allard2005novelmutationsof pages 1-3, watts2023internationalatherosclerosissociety pages 7-8)

Single-gene PCSK9 testing is reasonable when a familial variant is known. WES/WGS may identify deep-intronic, regulatory, or structural variants after a negative panel, but interpretation—not sequencing—is the chief limitation. RNA-seq or reporter assays remain research tools. CMA, karyotype, FISH, mitochondrial sequencing, and repeat-expansion testing are not routine.

Imaging is for complication assessment, not molecular diagnosis: coronary calcium/CT angiography may aid selected adult risk stratification; carotid ultrasound can show plaque. Routine pediatric coronary CT/calcium scoring is discouraged, whereas severe or homozygous-like presentations require specialist cardiovascular imaging. (watts2023internationalatherosclerosissociety pages 9-10)

Screening implementation

Cascade lipid and targeted-variant testing should begin with first-degree relatives and extend through the pedigree. Combined cascade testing and young-age universal screening could identify more than 90% of FH. Yet only about 10% of affected people worldwide are diagnosed, and over 80% of treated patients fail recommended LDL-C goals. (watts2023internationalatherosclerosissociety pages 1-2, watts2023internationalatherosclerosissociety pages 7-8)

11. Outcome and prognosis

Untreated prognosis is governed chiefly by cumulative LDL-C and other cardiovascular risks. General FH carries approximately tenfold higher coronary-heart-disease risk than the general population. ADH3-specific survival curves, five- or ten-year survival, disability rates, and validated prognostic models are unavailable. Severe D374Y disease and the myocardial-infarction death at age 49 in an F216L family illustrate the potential natural history but cannot define average prognosis. (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9, weider2017inhibitionofthe pages 152-156, abifadel2003mutationsinpcsk9 pages 2-2)

Adverse prognostic factors include higher untreated LDL-C, earlier xanthomas, established ASCVD, smoking, hypertension, diabetes, elevated lipoprotein(a), a second FH allele, and delayed/inadequate treatment. Favorable factors are early diagnosis, sustained LDL-C goal attainment, adherence, and control of all risk factors. Recovery from an established infarction or stroke is incomplete, but plaque progression and future events are preventable.

12. Treatment

ADH3 should be treated as high-risk heterozygous FH, intensified for severe phenotype or established ASCVD.

1. Lifestyle and risk-factor control: heart-healthy diet, physical activity, weight management, no smoking, and treatment of hypertension/diabetes. Lifestyle is adjunctive, not a substitute for medication.
2. High-intensity statin: atorvastatin or rosuvastatin unless contraindicated. Suggested NCIT concept: HMG-CoA reductase inhibitor therapy. Statin-associated muscle symptoms occur in roughly 10–15%; rhabdomyolysis is about 1–3 per 100,000 person-years and new-onset diabetes risk rises approximately 9% in broader populations. (fularski2024unveilingfamilialhypercholesterolemia—review pages 10-12)
3. Add ezetimibe: inhibits NPC1L1 intestinal cholesterol uptake; about 18% LDL-C lowering alone and about 20% additional lowering with a statin. Suggested NCIT: ezetimibe treatment. (fularski2024unveilingfamilialhypercholesterolemia—review pages 10-12)
4. Add PCSK9-directed treatment: alirocumab or evolocumab antibodies typically lower LDL-C about 60%; inclisiran suppresses hepatic PCSK9 synthesis. These are mechanistically well matched to PCSK9 GOF, although no genotype-specific randomized ADH3 trial was recovered. Injection-site reactions and flu-like symptoms are typical antibody adverse effects. (jeswani2024pcsk9inhibitorsthe pages 1-3, fularski2024unveilingfamilialhypercholesterolemia—review pages 10-12)
5. Further options: bempedoic acid, bile-acid sequestrants, or specialist combination therapy. Lipoprotein apheresis is reserved for exceptionally severe or refractory disease, especially biallelic/HoFH-like presentations.

ESC/EAS-derived general FH goals are at least a 50% LDL-C reduction and LDL-C below 70 mg/dL (1.8 mmol/L) for high-risk FH without ASCVD/major risk factors, or below 55 mg/dL (1.4 mmol/L) for very-high-risk disease. Children generally begin statins at 8–10 years; one guideline target after age 10 is below 135–140 mg/dL, adjusted to national guidance and risk. (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9)

Relevant registered studies found by the trial search include ORION-9 inclisiran in HeFH (NCT03397121, phase 3, 482 participants), pediatric evolocumab (NCT02624869, phase 3, 163), pediatric inclisiran (NCT06597019, recruiting phase 3, planned 60), and alirocumab plaque-burden assessment (NCT05465278, phase 4, 104). These enroll phenotypic FH, not specifically ADH3, and should not be presented as genotype-specific trials.

Emerging nucleic-acid and gene-editing approaches aim to silence or permanently disrupt hepatic PCSK9. They are conceptually attractive but experimental for inherited PCSK9 GOF and raise irreversibility, off-target, delivery, and long-term safety issues. DOI for a 2024 review: https://doi.org/10.1161/CIRCULATIONAHA.123.067957; August 2024.

Suggested CHEBI entities include cholesterol, LDL cholesterol/esterified cholesterol, atorvastatin, rosuvastatin, ezetimibe, and bempedoic acid. Suggested NCIT intervention classes include statin therapy, cholesterol-absorption inhibitor therapy, monoclonal-antibody therapy, small-interfering-RNA therapy, and therapeutic apheresis.

13. Prevention

Primary prevention of the genotype is impossible after conception. Reproductive options following counseling include prenatal diagnosis or preimplantation genetic testing for a known familial variant; decisions must remain nondirective.

Secondary prevention is central: childhood lipid screening, molecular confirmation, and cascade testing permit treatment before plaque develops. In a 2024 systematic review of 21 studies and 62 strategies, cascade screening was cost-effective in 78% of studies, opportunistic screening in 85%, systematic screening in 80%, and population-wide screening in 60%; cascade testing produced the greatest health benefit per person tested. DOI: https://doi.org/10.1007/s40273-023-01347-7; January 2024. (marquina2024costeffectivenessofscreening pages 1-2)

Tertiary prevention consists of sustained LDL-C reduction, smoking avoidance, blood-pressure and diabetes control, antiplatelet therapy when otherwise indicated, cardiac rehabilitation after events, and surveillance of established ASCVD. Vaccination and antimicrobial prophylaxis are not disease-specific interventions.

14. Other species and natural disease

No convincing naturally occurring veterinary syndrome caused by orthologous PCSK9 GOF was identified. Therefore, breed, VBO, natural-disease prevalence, zoonotic transmission, and cross-species transmission are not applicable/not established. PCSK9 is evolutionarily conserved across mammals, and engineered mouse, hamster, and pig systems reproduce LDLR depletion and hypercholesterolemia. All such examples should be annotated as experimental, not spontaneous disease. (rochemolina2015inductionofsustained pages 1-2, rochemolina2015inductionofsustained pages 10-10, matiasperez2021pcsk9geneparticipates pages 2-4)

Useful taxa include Mus musculus (NCBI Taxon 10090), Mesocricetus auratus (10036), and Sus scrofa (9823); ortholog identifiers should be drawn directly from current NCBI Gene/Alliance records during database curation.

15. Model organisms and experimental systems

• AAV-PCSK9-D374Y mouse: one intravenous AAV dose (3.5×10^10 viral particles) induced sustained LDL elevation in C57BL/6J, 129/Sv, and FVB mice. With high-fat diet, animals developed aortic plaques with macrophages and fibrous caps. In Apoe-null mice, D374Y doubled aortic-lesion extent despite unchanged serum cholesterol, suggesting downstream plaque effects or model interaction. DOI: https://doi.org/10.1161/ATVBAHA.114.303617; January 2015. (rochemolina2015inductionofsustained pages 1-2)
• Adenoviral PCSK9 models: murine PCSK9 increased total cholesterol about twofold and non-HDL cholesterol fivefold; human PCSK9 produced approximately ninefold higher LDL-C. Similar profiles in Ldlr-null mice established LDLR dependence. (weider2017inhibitionofthe pages 61-64)
• Humanized BAC mice: lines expressing approximately 95–5,000 ng/mL human PCSK9 showed expression-dependent increases in total cholesterol/apoB and reduced hepatic LDLR. (weider2017inhibitionofthe pages 152-156, weider2017inhibitionofthea pages 152-156)
• D374Y transgenic/viral models: D374Y increases LDLR affinity around tenfold; some engineered mice expressed about 14 μg/mL active PCSK9. (weider2017inhibitionofthe pages 152-156)
• Engineered minipigs: transgenic human PCSK9 GOF minipigs develop FH-like hypercholesterolemia and atherosclerosis, offering more human-like lipoprotein physiology than mice. The model is engineered, not natural disease. (rochemolina2015inductionofsustained pages 10-10, weider2017inhibitionofthe pages 64-68)
• Cell systems: HepG2, HuH7, primary hepatocytes, fibroblasts, and fluorescent PCSK9–LDLR trafficking assays test secretion, EGF-A binding, endocytosis, and lysosomal degradation. They are valuable for ACMG functional evidence but may not reproduce lifelong whole-body disease.

Major limitations are that mice lack CETP, viral overexpression may exceed physiological concentrations, liver-restricted vectors omit extrahepatic expression, and high-fat diets introduce environmental effects. BAC and large-animal models improve physiological relevance but remain costly and do not fully reproduce human coronary events. (weider2017inhibitionofthe pages 64-68)

Recent developments and principal evidence gaps

Notable 2023–2024 developments include stronger international emphasis on combined universal/cascade screening, implementation science addressing the evidence-to-practice gap, functional study of PCSK9 3′UTR variants, methylation as a possible FH risk biomarker, wider real-world use of inclisiran and PCSK9 antibodies, and preclinical nucleic-acid/gene-editing approaches. Up to 80–90% of FH remains undiagnosed, while most treated patients remain above goal, making implementation—not merely discovery of additional drugs—a major expert priority. (otero2024functionalanalysisof pages 4-5, marquina2024costeffectivenessofscreening pages 1-2, watts2023internationalatherosclerosissociety pages 1-2)

Critical ADH3-specific gaps are: population prevalence and penetrance; standardized functional classification of rare PCSK9 alleles; variant-specific response to antibodies versus inclisiran; prospective natural history; patient-reported quality of life; pregnancy outcomes; ancestry-diverse cohorts; and long-term safety of permanent PCSK9 editing.

Evidence-quality note

The strongest ADH3 evidence comprises the 2003 discovery pedigrees, later segregation studies, and convergent LDLR-trafficking experiments. Treatment targets and most quantitative outcome estimates are extrapolated from general HeFH because ADH3-specific randomized trials are absent. PMID values were not consistently exposed in the retrieved full texts; DOI URLs and publication dates are therefore supplied where verified rather than inventing PMID mappings.

References

1. (seidah2017thepcsk9revolution pages 3-6): Nabil G Seidah. The pcsk9 revolution and the potential of pcsk9-based therapies to reduce ldl-cholesterol. May 2017. URL: https://doi.org/10.21542/gcsp.2017.2, doi:10.21542/gcsp.2017.2. This article has 79 citations.

2. (abifadel2003mutationsinpcsk9 pages 2-2): Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich, Aurélie Derré, Ludovic Villéger, Michel Farnier, Isabel Beucler, Eric Bruckert, Jean Chambaz, Bernard Chanu, Jean-Michel Lecerf, Gerald Luc, Philippe Moulin, Jean Weissenbach, Annick Prat, Michel Krempf, Claudine Junien, Nabil G Seidah, and Catherine Boileau. Mutations in pcsk9 cause autosomal dominant hypercholesterolemia. Nature Genetics, 34:154-156, Jun 2003. URL: https://doi.org/10.1038/ng1161, doi:10.1038/ng1161. This article has 4016 citations and is from a highest quality peer-reviewed journal.

3. (fularski2024unveilingfamilialhypercholesterolemia—review pages 4-5): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 30 citations.

4. (mcnutt2010characterizationofthe pages 115-119): MC McNutt. Characterization of the non-proteolytic mechanism and cellular site of action of pcsk9-mediated degradation of the low-density lipoprotein receptor. Unknown journal, 2010.

5. (weider2017inhibitionofthea pages 152-156): E Weider. Inhibition of the proprotein convertase subtilisin/kexin type 9 (pcsk9) for the treatment of familial hypercholesterolemia. Unknown journal, 2017.

6. (allard2005novelmutationsof pages 3-6): Delphine Allard, Sabine Amsellem, Marianne Abifadel, Mélanie Trillard, Martine Devillers, Gérald Luc, Michel Krempf, Yves Reznik, Jean-Philippe Girardet, Alexandre Fredenrich, Claudine Junien, Mathilde Varret, Catherine Boileau, Pascale Benlian, and Jean-Pierre Rabès. Novel mutations of the pcsk9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Human Mutation, 26:497-497, Nov 2005. URL: https://doi.org/10.1002/humu.9383, doi:10.1002/humu.9383. This article has 269 citations and is from a domain leading peer-reviewed journal.

7. (allard2005novelmutationsof pages 1-3): Delphine Allard, Sabine Amsellem, Marianne Abifadel, Mélanie Trillard, Martine Devillers, Gérald Luc, Michel Krempf, Yves Reznik, Jean-Philippe Girardet, Alexandre Fredenrich, Claudine Junien, Mathilde Varret, Catherine Boileau, Pascale Benlian, and Jean-Pierre Rabès. Novel mutations of the pcsk9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Human Mutation, 26:497-497, Nov 2005. URL: https://doi.org/10.1002/humu.9383, doi:10.1002/humu.9383. This article has 269 citations and is from a domain leading peer-reviewed journal.

8. (weider2017inhibitionofthe pages 152-156): E Weider. Inhibition of the proprotein convertase subtilisin/kexin type 9 (pcsk9) for the treatment of familial hypercholesterolemia. Unknown journal, 2017.

9. (marquina2024costeffectivenessofscreening pages 1-2): Clara Marquina, Jedidiah I Morton, Melanie Lloyd, Dina Abushanab, Yeji Baek, Tamrat Abebe, Adam Livori, Padam Dahal, Gerald F. Watts, and Zanfina Ademi. Cost-effectiveness of screening strategies for familial hypercholesterolaemia: an updated systematic review. Pharmacoeconomics, 42:373-392, Jan 2024. URL: https://doi.org/10.1007/s40273-023-01347-7, doi:10.1007/s40273-023-01347-7. This article has 24 citations and is from a domain leading peer-reviewed journal.

10. (watts2023internationalatherosclerosissociety pages 7-8): Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, and Raul D. Santos. International atherosclerosis society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nature Reviews Cardiology, 20:845-869, Jun 2023. URL: https://doi.org/10.1038/s41569-023-00892-0, doi:10.1038/s41569-023-00892-0. This article has 300 citations and is from a domain leading peer-reviewed journal.

11. (yip2023geneticspectrumand pages 5-6): Man-Kwan Yip, Elaine Kwan, Jenny Leung, Emmy Lau, and Wing-Tat Poon. Genetic spectrum and cascade screening of familial hypercholesterolemia in routine clinical setting in hong kong. Nov 2023. URL: https://doi.org/10.3390/genes14112071, doi:10.3390/genes14112071. This article has 6 citations.

12. (fularski2024unveilingfamilialhypercholesterolemia—review pages 10-12): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 30 citations.

13. (fularski2024unveilingfamilialhypercholesterolemia—review pages 7-9): Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, and Beata Franczyk. Unveiling familial hypercholesterolemia—review, cardiovascular complications, lipid-lowering treatment and its efficacy. International Journal of Molecular Sciences, 25:1637, Jan 2024. URL: https://doi.org/10.3390/ijms25031637, doi:10.3390/ijms25031637. This article has 30 citations.

14. (watts2023internationalatherosclerosissociety pages 1-2): Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, and Raul D. Santos. International atherosclerosis society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nature Reviews Cardiology, 20:845-869, Jun 2023. URL: https://doi.org/10.1038/s41569-023-00892-0, doi:10.1038/s41569-023-00892-0. This article has 300 citations and is from a domain leading peer-reviewed journal.

15. (rochemolina2015inductionofsustained pages 1-2): Marta Roche-Molina, David Sanz-Rosa, Francisco M. Cruz, Jaime García-Prieto, Sergio López, Rocío Abia, Francisco J.G. Muriana, Valentín Fuster, Borja Ibáñez, and Juan A. Bernal. Induction of sustained hypercholesterolemia by single adeno-associated virus–mediated gene transfer of mutant hpcsk9. Arteriosclerosis, Thrombosis, and Vascular Biology, 35:50–59, Jan 2015. URL: https://doi.org/10.1161/atvbaha.114.303617, doi:10.1161/atvbaha.114.303617. This article has 234 citations and is from a domain leading peer-reviewed journal.

16. (rochemolina2015inductionofsustained pages 10-10): Marta Roche-Molina, David Sanz-Rosa, Francisco M. Cruz, Jaime García-Prieto, Sergio López, Rocío Abia, Francisco J.G. Muriana, Valentín Fuster, Borja Ibáñez, and Juan A. Bernal. Induction of sustained hypercholesterolemia by single adeno-associated virus–mediated gene transfer of mutant hpcsk9. Arteriosclerosis, Thrombosis, and Vascular Biology, 35:50–59, Jan 2015. URL: https://doi.org/10.1161/atvbaha.114.303617, doi:10.1161/atvbaha.114.303617. This article has 234 citations and is from a domain leading peer-reviewed journal.

17. (mcnutt2010characterizationofthea pages 115-119): MC McNutt. Characterization of the non-proteolytic mechanism and cellular site of action of pcsk9-mediated degradation of the low-density lipoprotein receptor. Unknown journal, 2010.

18. (otero2024functionalanalysisof pages 4-5): Javier Sanguino Otero, Carmen Rodríguez-Jiménez, Jose Mostaza Prieto, Carlos Rodríguez-Antolín, Ana Carazo Alvarez, Francisco Arrieta Blanco, and Sonia Rodríguez-Nóvoa. Functional analysis of 3′utr variants at the ldlr and pcsk9 genes in patients with familial hypercholesterolemia. Human Mutation, 2024:1-15, Feb 2024. URL: https://doi.org/10.1155/2024/9964734, doi:10.1155/2024/9964734. This article has 3 citations and is from a domain leading peer-reviewed journal.

19. (matiasperez2021pcsk9geneparticipates pages 2-4): D. MATÍAS-PÉREZ, A. PÉREZ-SANTIAGO, M. S. Sánchez Medina, JJ Alpuche Osorno, and I. GARCÍA-MONTALVO. Pcsk9 gene participates in the development of primary dyslipidemias. Balkan Journal of Medical Genetics : BJMG, 24:5-14, Jun 2021. URL: https://doi.org/10.2478/bjmg-2021-0009, doi:10.2478/bjmg-2021-0009. This article has 9 citations.

20. (weider2017inhibitionofthe pages 64-68): E Weider. Inhibition of the proprotein convertase subtilisin/kexin type 9 (pcsk9) for the treatment of familial hypercholesterolemia. Unknown journal, 2017.

21. (watts2023internationalatherosclerosissociety pages 9-10): Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, and Raul D. Santos. International atherosclerosis society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nature Reviews Cardiology, 20:845-869, Jun 2023. URL: https://doi.org/10.1038/s41569-023-00892-0, doi:10.1038/s41569-023-00892-0. This article has 300 citations and is from a domain leading peer-reviewed journal.

22. (jeswani2024pcsk9inhibitorsthe pages 1-3): Bijay Mukesh Jeswani, Shubhangi Sharma, Sawai Singh Rathore, Abubakar Nazir, Rohit Bhatheja, and Kapil Kapoor. Pcsk9 inhibitors: the evolving future. Health Science Reports, Oct 2024. URL: https://doi.org/10.1002/hsr2.70174, doi:10.1002/hsr2.70174. This article has 44 citations and is from a peer-reviewed journal.

23. (weider2017inhibitionofthe pages 61-64): E Weider. Inhibition of the proprotein convertase subtilisin/kexin type 9 (pcsk9) for the treatment of familial hypercholesterolemia. Unknown journal, 2017.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

12 of 13 terms resolved to a current term; the rest could not be looked up either way.